Intravenous immunoglobulin therapy for Miller Fisher syndrome.

Abstract

We analyzed clinical recovery of 92 patients with Miller Fisher syndrome who had been treated with IV immunoglobulin (IVIg; n = 28), plasmapheresis (n = 23), and no immune treatment (n = 41). IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of the disappearances of those symptoms were similar among three groups. In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery.

• Authors: Masahiro Mori, Satoshi Kuwabara, Toshio Fukutake, Takamichi Hattori
• Journal: Neurology (Neurology) Vol. 68 Issue 14 Pg. 1144-6 (Apr 03 2007) ISSN: 1526-632X [Electronic] United States
• PMID: 17404197 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Immunoglobulins, Intravenous

Topics

• Adolescent
• Adult
• Aged
• Female
• Follow-Up Studies
• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Male
• Middle Aged
• Miller Fisher Syndrome (drug therapy)
• Plasmapheresis (methods)